Non-profit organisation I-MAK is waging a global challenge against what it sees as invalid pharmaceutical patents, with access to life-saving drugs its main priority. LSIPR speaks to co-founder Tahir Amin to find out more.
The European Commission’s proposed export waiver for supplementary protection certificates has exposed a number of likely flaws which have not gone down well with patent owners. LSIPR reports.
Biologics patent owners should consider the US International Trade Commission as a supplement (or alternative) to district court litigation, say Filko Prugo, Charlotte Jacobsen, Matt Rizzolo and Henry Huang of Ropes & Gray.
A recent case in India reveals the various ways in which pharmaceutical patents can be challenged, as Neeti Wilson, Arpita Kulshreshtha and Gitika Suri of Anand and Anand report.
Mark Remus of Brinks Gilson & Lione discusses two patent-related challenges for generic pharmaceutical companies and how they might be overcome.
The European Commission’s proposed export waiver for supplementary protection certificates is likely to face opposition and may be delayed by EU parliamentary changes, says Trevor Cook of WilmerHale.
Brian Anderson was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.
Following a CJEU decision in July, and with two more cases on the horizon, Joel Beevers and Michael Pears of Potter Clarkson report on whether an active ingredient (or combination of active ingredients) is ‘protected by a basic patent’, as required for a supplementary protection certificate.
If enacted by Congress, the proposed amendment to the Hatch-Waxman Act would spell trouble for generic pharmaceutical companies seeking to take on brand competitors in patent litigation, says Janine Carlan of Arent Fox.
Patrick Leahy was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the government and policy section, as LSIPR reports.